TY - JOUR T1 - Gemcitabine and Oral Vinorelbine as Salvage Treatment in Patients with Advanced Anthracycline- and Taxane-pretreated Breast Cancer JF - Anticancer Research JO - Anticancer Res SP - 2989 LP - 2992 VL - 27 IS - 4C AU - A. ARDAVANIS AU - P. KOUNTOURAKIS AU - S. MALIOU AU - M. VASSILAKOPOULOU AU - S. BASIOUKAS AU - F. KYRIAKOU AU - S. KOUMNA AU - G. RIGATOS Y1 - 2007/07/01 UR - http://ar.iiarjournals.org/content/27/4C/2989.abstract N2 - Background: Despite progress achieved with new chemotherapeutic and endocrine agents, advanced breast cancer (ABC) remains a disease with poor prognosis. We sought to determine the efficacy of gemcitabine (GC) and oral vinorelbine (VB) in heavily preatreated ABC. Patients and Methods: Patients previously treated with anthracyclines and taxanes in the metastatic setting with progressive disease were eligible. Treatment consisted of VB (60 mg/m2, orally) and GC (1000 mg/m2, intravenous infusion), every two weeks of a 28-day cycle. Results: Thirty-one patients with ABC were enrolled. Toxicity was acceptable, mainly haematological. Three and 8 patients achieved a complete (9.6%) and partial (25.8%) response, respectively; ten patients (32.2%) had stable disease. Median time-to-progression was 5.3 months, while in responders 8.6 months. Median overall survival was 14 months. Conclusion: Oral VB and GC is an active and well-tolerated combination in anthracycline/taxane-pretreated ABC, representing an interesting option in this poor prognosis group of patients. ER -